About Kejako
Kejako is a Healthcare company based in Plan-les-ouates (Switzerland) founded in 2015 by David ENFRUN and Gilles Bos. It operates as a medical devices for ophthalmic surgery are researched and developed. Kejako has raised $807.48 thousand across 2 funding rounds from investors including Fongit Seed Invest and Business Angels Switzerland. Its chief executive is David ENFRUN. Kejako offers products and services including Presbyopia Treatment. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is Kejako SA. Its competitors include Clerio Vision, IntraLase, WaveLight, Technolas Perfect Vision and Xianwei Vision Technology and 4 more; 3 of its 9 listed competitors have raised funding.
Company details
Kejako was established in 2015 by co-founders David Enfrun, who serves as CEO, and Gilles Bos. Focus is placed on research and development within the medical device sector, specifically for ophthalmic surgery applications. Operations involve the creation of specialized tools and technologies to support surgical procedures in eye care. The company is based in the healthcare technology field, with activities directed toward advancing ophthalmic innovations.
- Headquarters Plan-les-ouates, Switzerland
- Founders David ENFRUN, Gilles Bos
- SectorsHealthcare
- Website kejako.com
- Social LinkedIn
- Legal Name Kejako Sa
- Total Equity Funding$807.48K (USD)
in 2 rounds
- Latest Funding Round$807.48K (USD), Seed
Mar 2018
- InvestorsFongit Seed Invest
& 1 more
Products & Services of Kejako
Kejako offers a comprehensive portfolio of products and services, including Presbyopia Treatment.
Personalized non-surgical laser solution to reverse presbyopia in midlifers.
Funding Insights of Kejako
Kejako has successfully raised a total of $807.48K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $807.48 thousand completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $807,476
- Total Rounds 2
- Last Round Seed — $807,476
- Investors Count 2
All 2 funding rounds of Kejako with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $807,476 | Seed | – | – | |
| Feb 2018 | – | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Kejako
Kejako has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Fongit Seed Invest and Business Angels Switzerland.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | fongitseedinvest.com | - | |
Business Angels Switzerland is focused on investing in innovative startups. | – | businessangels.ch | Worb, Switzerland |
Investor details for Kejako
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kejako
2 people are tracked at Kejako (2 in leadership).
| Name | Role | Group |
|---|---|---|
David ENFRUN | Co-Founder & CEO | Leadership |
Gilles Bos | Co-Founder | Leadership |
Complete people profiles for Kejako
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kejako
3 dated milestones of Kejako across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Kejako is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $807K.
Competitors of Kejako
Kejako has 9 listed competitors in our database, 3 of them funded. They include Clerio Vision, IntraLase, WaveLight, Technolas Perfect Vision and Xianwei Vision Technology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cleriovision.com | 2014 | Rochester, United States | $28.95M | 90 | Laser induced change in refractive index | |
| intralase.com | 1997 | Irvine, United States | $29.5M | – | Femtosecond laser technology is developed for eye surgery procedures. | |
| wavelight.de | 1996 | Erlangen, Germany | – | 320 | Diagnostic and surgical technologies for vision correction are provided. | |
| technolaspv.com | 2008 | Munich, Germany | – | 163 | Femtosecond and excimer lasers for ophthalmology are designed and produced. | |
| xianweivisiontechnology.tcc.mode | 2022 | Nanjing, China | – | – | Femtosecond laser-based devices for ophthalmic myopia correction are developed. | |
| customvis.com | 2001 | Perth, Australia | – | – | Surgical laser vision correction technology is provided for ophthalmologists. | |
| lenticularresearchgroup.com | 2007 | Naperville, United States | $330,000 | – | Developer of laser device for treating the cause of presbyopia | |
| optotek-medical.com | 1990 | Ljubljana, Slovenia | – | – | Optical and laser solutions for ophthalmic treatments are developed. | |
| tklaser.com | 2006 | Tianjin, China | – | – | Manufactures and supplies medical lasers. |
Detailed competitors of Kejako
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
10 companies that operate in the same segment as Kejako (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kejako
Complete news archive for Kejako
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kejako
Kejako was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Kejako is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
David ENFRUN is the current CEO of Kejako. They have also founded this company.
Kejako is a funded company, having raised a total of $807.48K across 2 funding rounds to date.
Kejako was established in 2015 by co-founders David Enfrun, who serves as CEO, and Gilles Bos. Focus is placed on research and development within the medical device sector, specifically for ophthalmic surgery applications. Operations involve the creation of specialized tools and technologies to support surgical procedures in eye care. The company is based in the healthcare technology field, with activities directed toward advancing ophthalmic innovations.
Kejako's top competitors include Clerio Vision, IntraLase and WaveLight.
Kejako offers Presbyopia Treatment.
Kejako has 2 investors. Key investors include Fongit Seed Invest, and Business Angels Switzerland.
Kejako operates through Kejako Sa.